Nina(Das)ShahMD

PubMed

• 12 citations
  Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.
  Hossein Maymani, Paul Lin, Rima M. Saliba, Uday R. Popat, Qaiser Bashir
  Biology of Blood and Marrow Transplantation. 2017-03-01
• 20 citations
  Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma
  Sathish Kumar Gopalakrishnan, Anita D'Souza, Emma C. Scott, Raphael Fraser, Omar Davila
  Biology of Blood and Marrow Transplantation. 2019-04-01
• 168 citations
  Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
  Edward A. Stadtmauer, Marcelo C. Pasquini, Beth Blackwell, Parameswaran Hari, Asad Bashey
  Journal of Clinical Oncology. 2019-01-17

Journal Articles

• Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction Drugs  
  Krina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature

Abstracts/Posters

• Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
  Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
  Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma
  Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation
  Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and _Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology
  Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Germline Variation Predicts Treatment Response in Multiple Myeloma
  Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)Clinically Relevant Abstract
  Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM)
  Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Cord Blood Regulatory T Cells Prevent Mutiple Myeloma Progression By Suppressing Inflammation
  Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in C... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Immunotherapy in Myeloma 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Daratumumab (DARA) Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma (NDMM) after Frontline Autolo... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019